Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: Multicenter study in Japan

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 20, Issue 3, 1998, Pages 227-235

  Nishimura, T ^a   Takeda, M ^b   Nakamura, Y ^b   Yosbida, Y ^c   Arai, H ^d   Sasaki, H ^d   Shouji, M ^e   Hirai, S ^f   Khise, K ^g   Tanaka, K ^h   Hamamoto, M ^h   Yamamoto, H ⁱ   Matsubayashi, T ^j   Urakami, K ^k   Adachi, Y ^k   Nakashima, K ^k   Toji, H ^l   Nakamura, S ^l   Yoshida, H ^m  

^a KOSHIEN UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c Department of Pathology   (Japan)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e GUNMA UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^g Department of Dentistry Oral surgery   (Japan)

^h Tokyo Metropolitan Tama Geriatric Hospital   (Japan)

ⁱ Osaka City Kosaiin Hospital   (Japan)

^j Hanwa Senboku Hospital   (Japan)

^k TOTTORI UNIVERSITY   (Japan)

^l HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^m Nissho Corporation   (Japan)

more..

Author keywords

Alzheimer's dementia; Cerebrospinal fluid; ELISA; Tau

Indexed keywords

BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JAPAN; REPRODUCIBILITY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 7144256256     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Nishimura, T. Alzheimer's disease. Pick's disease and subcortical dementia. Jpn J Clin Med 1992, 50: 63-70.
2. Yoshida, T., Hasegawa, M., Noda, Y., Nabeshima, T. The domestic states of development of cognitive enhancers for senile dementia of Alzheimer's type. Dementia 1995, 9: 233-45.
3. Khachaturian, Z.S. Diagnosis of Alzheimer's disease. Arch Neurol 1985, 42: 1097-105.
4. Otsuka, T. Dementia rating scales with test method and their problems. A. Dementia rating scales developed in Japan. Dementia 1996, 10: 245-58.
5. Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Babour, R. et al. Reduction of P amyloid peptide in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38: 643-8.
6. Van Nostrand, W.E., Wagner, S.L., Shankle, W.R., Farrow, J.S. et al. Decreased levels of soluble amyloid P -protein precursor in cerebrospinal fluid of live Alzheimer disease biochemical marker for Alzheimer-type dementia. Annals of Neurology 1990, 28: 561-7.
7. 1-Antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Annals of Neurology 1990, 28: 561-7.
8. Wang, G.P., Iqbal, K., Bucht, C., Winblad, B. et al. Alzheimer's disease: Paired helical filament immunoreactivity in cerebrospinal fluid. Acta Neuropathol 1991, 82: 6-12.
9. Aral, H., Terajima, M., Miura, M., Higuchi, S. et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995, 38: 649-52.
10. Corder, E.H., Saunders, A.M., Strittmatter, W., Schmechal, D.E. et al. Gene dose of apolipoprotein E type 4 alle and the risk of Alzheimer's disease in late onset families. Science 1993, 261: 921-23.
11. Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J. et al. Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993, 61: 1828-34.
12. Mori, H., Hosoda, K., Matsubara, E., Nakarnoto, T. et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau Neuroci Lett 1995, 186: 181-3.
13. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price. D., Stadlan, E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34: 939-44.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association: Washington, D.C. 1992.
15. Reisberg, B., Ferris, S.H., Anand, R. et al. Functional staging of dementia of the Alzheimer type. Ann NY Acad Sci 1984, 48: 278-81.
16. Takeda, M., Kudo, T., Taniguchi, N., Nishimura, T. Neurofibrillary changes and phosphorylated tau of Alzheimer's disease. Jpn J Geriat 1996, 33: 169-72.
17. Isoe, K., Urakami, K., Shimomura, T., Wakutani, Y. et al. Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: A longitudinal study. Dementia 1996, 7: 175-6.
18. Terajima, M., Arai, H., Itabashi, S., Higuchi, M. et al. Elevated cerebrospinal fluid tau levels: implications for the early diagnosis of Alzheimer's disease. J Am Geriatr Soc 1996, 44: 1012-3.
19. Hock, C., Golombowski, S., Naser, W., Muller-Spahn, F. Increased levels of protein in cerebrospinal fluid of patients with Alzheimer's disease-Correlation with degree of cognitive impairment. Ann Neurol 1995, 37: 414-5.
20. Jensen, M., Basun, H., Lantelt, L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995, 186: 189-91.